{"id":3995,"date":"2025-09-22T16:35:53","date_gmt":"2025-09-22T14:35:53","guid":{"rendered":"https:\/\/www.esptcongress.org\/?page_id=3995"},"modified":"2025-10-08T10:35:29","modified_gmt":"2025-10-08T08:35:29","slug":"molden-espen","status":"publish","type":"page","link":"https:\/\/www.esptcongress.org\/index.php\/molden-espen\/","title":{"rendered":"Molden Espen"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;1\/4&#8243;]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">\/*\nImpossibile accedere al file di sistema.\n*\/<\/style><div class=\"shortcode-single-image-wrap shortcode-single-image-84332439787d762ed35ea02d189393cc alignnone  vc_custom_1758551140119 enable-bg-rollover dt-icon-bg-off\" ><div class=\"shortcode-single-image\"><div class=\"fancy-media-wrap  layzr-bg\" style=\"\"><img fetchpriority=\"high\" decoding=\"async\" class=\"preload-me lazy-load aspect\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D&#39;http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg&#39;%20viewBox%3D&#39;0%200%20500%20500&#39;%2F%3E\" data-src=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Molden_foto-500x500.jpg\" data-srcset=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Molden_foto-500x500.jpg 500w, https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Molden_foto-600x600.jpg 600w\" loading=\"eager\" sizes=\"(max-width: 500px) 100vw, 500px\" width=\"500\" height=\"500\"  data-dt-location=\"https:\/\/www.esptcongress.org\/index.php\/speakers\/molden_foto\/\" style=\"--ratio: 500 \/ 500;\" alt=\"\" \/><\/div><\/div><\/div><div class=\"standard-arrow list-divider bullet-top\"><ul>\n<li>Dr. Molden Espen<\/li>\n<\/ul>\n<\/div>[\/vc_column][vc_column width=&#8221;3\/4&#8243;]<div id=\"ultimate-heading-373069f30c8f49a85\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-373069f30c8f49a85 uvc-1120 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-373069f30c8f49a85 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;\">CV<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-373069f30c8f49a85 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\"><strong>Present positions<\/strong><br \/>\n\u2022 Research Head, Center for Psychopharmacology, Diakonhjemmet Hospital<br \/>\n\u2022 Professor, Section for Pharmacology and Pharmaceutical Biosciences, University of Oslo<\/p>\n<p><strong>Degrees<\/strong><br \/>\n\u2022 MSc at School of Pharmacy, University of Oslo (1997)<br \/>\n\u2022 PhD at Department of Pharmacology, School of Pharmacy, University of Oslo (2003)<\/p>\n<p><strong>Research field<\/strong><br \/>\n\u2022 Clinical pharmacology\/psychopharmacology with focus on genetics, patient factors and drug-drug interactions as sources to variability in drug response, and strategies to manage this variability in clinical practice to improve treatment outcome<\/p>\n<p><strong>Publications<\/strong><br \/>\n\u2022 202 papers in PubMed-indexed journals<\/p>\n<p><strong>Supervision<\/strong><br \/>\n\u2022 Supervisor of 17 completed PhD students<br \/>\n\u2022 Supervisor of &gt;50 completed master students<\/div><\/div><div id=\"ultimate-heading-127269f30c8f49add\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-127269f30c8f49add uvc-9486 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-127269f30c8f49add h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;margin-top:50px;\">ABSTRACT<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-127269f30c8f49add .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\"><strong>Clinical Implementation<\/strong><br \/>\n<strong>COMPLEMENTARY USE OF PGX AND TDM IN ANTIDEPRESSIVE TREATMENT<\/strong><br \/>\nE. Molden 1<br \/>\n1Center for Psychopharmacology, Diakonhjemmet Hospital, and University of Oslo, Oslo, Norway<\/p>\n<p><strong>BACKGROUND-AIM<\/strong><br \/>\nIndividual variability in clinical response of antidepressant treatment is extensive. The underlying causes are complex,<br \/>\nbut patient differences in serum concentrations obtained at similar dosing of the same drug represent a key dimension.<br \/>\nThe aim of the presentation is to provide an overview of how pharmacogenetic (PGx) and therapeutic drug monitoring<br \/>\n(TDM) analyses can be combined for personalized dosing of antidepressants to achieve target serum concentrations.<\/p>\n<p><strong>METHODS<\/strong><br \/>\nExperiences from a laboratory service performing both PGx and TDM analyses to guide dosing of selected<br \/>\nantidepressants will illustrate how these tools are used in clinical practice in Norway. Research within the field provides<br \/>\na basis for outlining a rational approach for combining the use of PGx and TDM to optimize dosing and improve<br \/>\noutcomes of antidepressant treatment.<\/p>\n<p><strong>RESULTS<\/strong><br \/>\nMost antidepressants are metabolized by CYP2D6 or\/and CYP2C19, where individual variability in phenotypes is<br \/>\nstrongly determined by genetic variability. Many studies with different antidepressants, e.g. escitalopram, sertraline,<br \/>\nvenlafaxine and vortioxetine, show that CYP2D6 or\/and CYP2C19 genotype is associated with variability in serum<br \/>\nconcentrations and treatment outcomes, such as drug switch and discontinuation. While PGx analyses related to<br \/>\nantidepressant treatment today is mainly reactive (in Norway) due to outside target TDM levels or unsuccessful<br \/>\noutcomes, future use probably would align to a concept of pre-emptive, PGx-guided starting dose. Although<br \/>\nimproved mental health and substantial cost savings are estimated benefits of using pre-emptive genotyping when<br \/>\nprescribing antidepressant drugs, TDM-based dose tuning may increase patient proportions reaching target levels of<br \/>\nantidepressants, since unknown genetic factors as well as non-genetic factors, e.g. age and drug-drug interactions,<br \/>\nare also determinant of drug concentrations. Furthermore, pre-emptive use of PGx analyses for personalized dosing<br \/>\nof antidepressants drugs should consider the number-needed-to-genotype (NNG) to identify the most vulnerable<br \/>\npatients, i.e. poor or ultrarapid metabolizers. Another issue is the precision of diplotype activity scores in predicting<br \/>\nindividual metabolizer phenotype, which should be critically assessed.<\/p>\n<p><strong>CONCLUSIONS<\/strong><br \/>\nComplementary use of PGx and TDM analyses for individual dosing of antidepressive drugs likely increase treatment<br \/>\nsuccessfulness compared to applying either tool separately.<\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3995","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/comments?post=3995"}],"version-history":[{"count":4,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3995\/revisions"}],"predecessor-version":[{"id":4131,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3995\/revisions\/4131"}],"wp:attachment":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/media?parent=3995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}